Teva Pharmaceutical Industries (TEVA.TA) Stock Price
Teva Pharmaceutical Industries Price
Revenue has compounded at 4.3% per year over the past 19 years to 18.68 B USD. Earnings per share have grown at 3.2% per year over the last 19 years. Teva Pharmaceutical Industries's net margin stands at 8.2%, up from 2.6% several years earlier. Teva Pharmaceutical Industries currently offers a dividend yield of about 7.40%. The dividend has grown at 7.8% per year over the past 11 years. Analysts set a median price target of 10.80 USD, implying 74.3% below the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Teva Pharmaceutical Industries stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Teva Pharmaceutical Industries business model & stock analysis
Frequently asked questions about Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd is a globally renowned pharmaceutical company. The company's business model centers around developing, manufacturing, and distributing generic and specialty medicines. With a focus on improving access to affordable healthcare, Teva offers a wide range of high-quality pharmaceutical products for various therapeutic areas. By combining its innovative research and development capabilities with extensive global reach, Teva aims to provide cost-effective solutions to patients worldwide. As a leading generics manufacturer, Teva leverages its expertise to deliver safe and effective medications, contributing to better healthcare outcomes globally.
Teva Pharmaceutical Industries Ltd is primarily active in the pharmaceutical industry.
The main competitors of Teva Pharmaceutical Industries Ltd in the market include companies such as Pfizer, Novartis, Mylan, Johnson & Johnson, and GlaxoSmithKline. These companies also operate in the pharmaceutical industry and compete with Teva in areas such as generic drugs, specialty pharmaceuticals, and innovative health solutions.
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company. Founded in 1901, Teva has a rich history and impressive background. Originally established in Jerusalem, Israel, Teva has grown to become the world's largest manufacturer of generic drugs. With a global network of research and development centers, manufacturing sites, and commercial operations in over 60 countries, Teva is committed to improving health and increasing access to high-quality healthcare solutions worldwide. The company has a diverse portfolio of products, spanning multiple therapeutic areas, including specialty medicines, generic drugs, and over-the-counter products. Teva's dedication to innovation, quality, and affordability has made it a trusted name in the pharmaceutical industry.
Teva Pharmaceutical Industries Ltd has achieved significant milestones throughout its history. The company became the largest generic drug manufacturer in the world, offering affordable healthcare solutions to millions of patients worldwide. Teva's acquisition of Actavis Generics further enhanced its global market presence. It pioneered the development of cutting-edge medications and continues to drive innovation in the pharmaceutical industry. Teva's commitment to quality and patient-centric approach have earned it numerous recognitions and awards, solidifying its position as a leader in the market. With a dedicated focus on improving people's lives through accessible medicines, Teva Pharmaceutical Industries Ltd stands as a prominent player in the healthcare sector.
Teva Pharmaceutical Industries Ltd is primarily present in various countries and regions globally. Some key regions include North America, Europe, Asia Pacific, Latin America, and the Middle East. In North America, Teva has a significant presence in the United States and Canada. In Europe, the company operates in countries such as Germany, France, Spain, Italy, and the United Kingdom. Teva also has a strong presence in countries like China, Japan, India, Australia, and South Korea, among others, in the Asia Pacific region. Moreover, Teva Pharmaceutical Industries Ltd has expanded its reach to Latin American countries like Brazil and Mexico, as well as the Middle East region.
Teva Pharmaceutical Industries Ltd represents values of integrity, quality, and accessibility in the pharmaceutical industry. With a strong corporate philosophy focused on making a positive impact on global health, Teva strives to provide affordable and innovative healthcare solutions to people around the world. By prioritizing patient needs, Teva emphasizes ethical business practices and promotes sustainable growth. As a leading global pharmaceutical company, Teva's commitment to improving and saving lives is evident in its extensive product portfolio, research initiatives, and dedication to making healthcare accessible to all.
Analysts currently set an average price target of 10.80 USD for the Teva Pharmaceutical Industries stock (median: 10.80 USD), implying -74.3 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Teva Pharmaceutical Industries stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Teva Pharmaceutical Industries to generate revenue of 16.75 B USD and earnings per share of 2.03 USD.
Converted at the current exchange rate, the Teva Pharmaceutical Industries share trades at 37.34 EUR (41.95 USD).
Teva Pharmaceutical Industries Ltd is one of the largest and most well-known pharmaceutical companies worldwide. The company is based in Israel and employs over 45,000 people around the world. It operates in various divisions and offers a wide range of products. The company's divisions include generics, specialty pharmaceuticals, and biopharmaceuticals. In the generics division, Teva offers a variety of generic medications that are available at an affordable price. These medications are essentially copies of brand-name drugs that are already on the market. Teva also operates in the specialty pharmaceuticals division. Here, the company focuses on the development and marketing of medications for rare diseases. These medications treat diseases where there are either no treatment options or where existing treatments are ineffective. The company is also active in the biopharmaceuticals division, where it focuses on the development and marketing of biologics. Biologics are medications made from living organisms. They are used to treat diseases such as cancer, arthritis, and multiple sclerosis. Some of Teva's products include Copaxone, Azilect, Qvar, ProAir, and NuvaRing. Copaxone is a medication for the treatment of multiple sclerosis and is Teva's top-selling drug. Azilect is used to treat Parkinson's disease. Qvar and ProAir are asthma medications, and NuvaRing is a hormonal contraceptive. Teva's business model is based on the development and marketing of pharmaceutical products to improve people's health. The company generates revenue through the sale of its products. Teva is a major player in the generic market and has a significant market share in this division. The company also has a strong presence in the specialty pharmaceuticals market. Teva also utilizes partnerships and acquisitions to expand its business and enter new markets. An important acquisition for Teva was the acquisition of Actavis Generics, which made Teva one of the largest generic pharmaceutical companies in the world. Overall, Teva Pharmaceutical Industries Ltd is a leading pharmaceutical company that offers a wide range of products and operates in various divisions. The company has a strong presence in the generic market and also focuses on the development of medications for rare diseases and biopharmaceuticals. Teva is expected to continue to grow and enter new markets through partnerships and acquisitions.
The expected revenue of Teva Pharmaceutical Industries is 16.75 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Teva Pharmaceutical Industries is 2.38 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Teva Pharmaceutical Industries is currently 20.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Teva Pharmaceutical Industries stock.
The price-to-sales ratio (P/S) of Teva Pharmaceutical Industries is currently 2.94. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Teva Pharmaceutical Industries stock.
The Eulerpool Quality Score for Teva Pharmaceutical Industries is 5/10.
The ISIN of Teva Pharmaceutical Industries is IL0006290147. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Teva Pharmaceutical Industries is 906517. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Teva Pharmaceutical Industries is TEVA.TA. The ticker symbol is used to trade Teva Pharmaceutical Industries shares on the stock exchange.
Teva Pharmaceutical Industries stock
Teva Pharmaceutical Industries Peer Group
Teva Pharmaceutical Industries Ticker
Teva Pharmaceutical Industries FIGI
All fundamentals and in-depth analysis of Teva Pharmaceutical Industries
Our stock analysis for Teva Pharmaceutical Industries stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Teva Pharmaceutical Industries. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.